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Background: Patients with severe or very severe chronic obstructive pulmonary disease (COPD)
frequently suffer repeated exacerbations generating high health care utilization costs. Com-
bined corticosteroid and bronchodilator treatment using a single inhaler might - via improved
compliance - reduce exacerbation rates.
Objectives: Our aim was to obtain descriptive data on exacerbation rates in patients with se-
vere or very severe COPD (GOLD Stages III and IV as per GOLD 2009 classification) receiving sal-
meterol xinafoate/fluticasone propionate via a single inhaler (SFC) or via separate inhalers
(Sal/FP) in addition to individual existing therapy in order to investigate the potential benefit
of a fixed combination device as compared with two separate devices due to potentially im-
proved patients’ compliance.
Methods: This prospective, randomized, open-label, parallel-group, multi-center, exploratory
study was conducted in Germany in 2007e2009. Patients were required to have suffered  2
moderate/severe exacerbations in the preceding year.
Results: 213 patients (SFC: 108 patients, Sal/FP: 105 patients) from 23 centers were evalu-
ated. Approximately 25% of patients showed COPD Stage IV. On average patients had suffered
2.3  0.6 moderate/severe exacerbations in the preceding year. The annual rate of moderate/
severe exacerbations observed in the study was similar in both treatment groups (SFC:
0.86  0.13; Sal/FP: 0.86  0.14; exacerbation rate ratio SFC/Sal/FP: 1.00; pZ 0.73; negative0 8990 3706; fax: þ44 20 8990 3501.
n@gsk.com (C. Hagedorn).
3 Elsevier Ltd. All rights reserved.
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Salmeterol/fluticasone in COPD GOLD Stage III/IV 543binomial model). Compliance was high and comparable in both groups. Besides COPD exacer-
bations, pneumonia (5.6%) and nasopharyngitis (5.2%) were the most common adverse events.
Conclusion: Observed exacerbation rates were lower than those reported at baseline. No sub-
stantial difference was observed between administration of salmeterol xinafoate/fluticasone
propionate via a single inhaler and separate inhalers. Treatment was safe and well tolerated.
ClinicalTrials.gov Identifier: NCT00527826.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
COPD is a disease with rising morbidity and mortality. Ac-
cording to the WHO Global Burden of Disease report (up-
date 2004) COPD is projected to be amongst the 4 leading
causes of death in 2030.
Currently there are three established non-
pharmacological interventions available that may have an
impact on disease progression and modify the natural his-
tory of COPD: Smoking cessation, long-term oxygen therapy
in patients who are hypoxemic and, possibly, lung volume
reduction surgery or lung transplantation.1 Established
pharmacological therapies include bronchodilators (mainly
b2-agonists and anticholinergics) used singly or in combi-
nation and inhaled corticosteroids (ICS) which are recom-
mended to be added in patients with severe and very
severe COPD and repeated exacerbations.2
Some of these therapies have recently been shown to
positively modify disease progression (defined by decline in
FEV1 [forced expiratory volume in one second] over time) as
we have learned from the TORCH study.3 The salmeterol
xinafoate/fluticasone propionate (SFC 50/500 mg) Diskus
combination product combines the inhaled corticosteroid
fluticasone propionate with the long-acting b2-adrenergic
bronchodilator salmeterol xinafoate in a single multi-dose
powdered inhaler. This product is currently licensed for
the treatment of COPD in patients with FEV1 <60% and
a history of recurrent exacerbations.
The single components salmeterol xinafoate (Sal) and
fluticasone propionate (FP) have been demonstrated to
decrease the occurrence of exacerbations in patients with
COPD. Sal reduced the exacerbation rate and delayed the
time to first exacerbation compared to placebo4; similar
results were obtained for FP.5,6 Studies with the combina-
tion inhaler SFC showed improvements in lung function and
quality of life and a reduced rate of moderate and severe
exacerbations as compared to placebo.7,8 Kardos et al.
compared the combination inhaler SFC with salmeterol
xinafoate monotherapy in patients with severe COPD and
found a significantly lower exacerbation rate under SFC.9
Although treatment guidelines (GOLD2) recommend the
addition of inhaled corticosteroids in patients with severe
and very severe COPD and repeated exacerbations, many of
these patients are only treated with a combination of b2-
agonists and anticholinergics whilst inhaled corticosteroids
are often not added. Patients with severe and very severe
COPD have a high risk of developing recurrent exacerba-
tions10,11 and the therapy of these exacerbations often re-
quires prolonged hospital stays, intensive care unit
treatment and other measures that increase overall health
care utilization costs. The addition of inhaled corticosteroidsapplied to reduce exacerbations might reduce the overall
health care utilization costs for these patients, and a fixed
combination devicemight - via improved patient compliance
- be more effective than two separate devices.
We designed this study to obtain descriptive data on
exacerbation rates and direct costs associated with COPD in
a patient population with a considerable proportion of
GOLD Stage IV patients treated with either the combination
product SFC or the single inhalers Sal/FP. Our aim was to
evaluate differences between SFC and Sal/FP which might
have been the result of pharmacological synergy or, most
probably, of enhanced adherence to fixed combination
therapy. In order to maximize the chance of demonstrating
differences in compliance-mediated effectiveness we
decided on an open-label, parallel-group design which
corresponds more to real-life conditions.
Methods
Study design
This prospective, randomized, open-label, parallel-group,
multi-center study was carried out in Germany between
November 2007 and July 2009.
Study assessments were performed at 6 study visits in
total, at intervals of 2e3 months over 52 weeks. Additional
telephone visits were conducted every 4 weeks between
the scheduled visits. Baseline data were collected for all
patients at Visit 1 and eligible patients were randomized to
receive salmeterol xinafoate/fluticasone propionate either
in a fixed combination via a single inhaler or via 2 separate
inhalers. Randomization was performed in a stratified
manner according to COPD severity (severe/very severe).
The protocol was approved by the Central Ethics Com-
mittee and all patients provided written informed consent.
Patient population
Male or female patients aged 40 years with a diagnosis of
COPD (based on the American Thoracic Society [ATS]/Eu-
ropean Respiratory Society [ERS] criteria1) were eligible for
inclusion if they presented with GOLD2 Stage III or IV
(baseline post-bronchodilator FEV1 <50% predicted and
FEV1/IVC ratio <70%). Patients were further required to
have suffered - during the 12 months before randomization
- 2 or more moderate or severe exacerbations leading to
medical consultation. Furthermore, stable COPD medi-
cation during the 4 weeks prior to randomization and
a history of smoking with at least 10 pack years were
mandatory. Key exclusion criteria were the presence of
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nificant inflammatory disease other than COPD, chronic or
prophylactic antibiotic therapy and moderate or severe
COPD exacerbation or lower respiratory tract infection
during the 4 weeks prior to randomization. Maintenance
therapy with systemic steroids at study start was not
permitted.
Treatment
Treatment consisted of salmeterol xinafoate 50 mg and
fluticasone propionate 500 mg inhalation powder at a dos-
age of 1 inhalation twice a day (morning and evening)
either via a single Diskus inhaler (SFC group) or via 2
separate Diskus inhalers (Sal/FP group) in addition to in-
dividual existing therapy.
Statistical analysis
The primary endpoint was the rate of exacerbations (Grade
II and III) during the treatment period of 52 weeks. Exac-
erbations were defined according to Rodriguez-Roisin12
with moderate (Grade II) exacerbations entailing a worsen-
ing of COPD symptoms that required both a change of res-
piratory medication (increased dose of prescribed or
addition of new drugs) and medical assistance, and severe
(Grade III) exacerbations entailing a deterioration in COPD
resulting in hospitalization or emergency room treatment.
According to the exploratory character of the study,
analyses of the primary and secondary endpoints were
descriptive. The exacerbation rate (per year) was com-
pared between the two treatment groups (based on the
intent-to-treat population, ITT) by calculating a negative
binomial model with treatment duration (in years) as
offset-term. The model included the factors treatment and
severity of COPD (stratum recalculated from lung function
parameters; GOLD 2009 classification) as a fixed effect and
the interaction term between treatment and severity of
COPD. Estimates for annualized exacerbation rates (adjus-
ted for the mentioned factors) were calculated taking into
account the imbalance of strata (fixed rate of 73% severe
COPD versus 27% very severe COPD according to the
observed rates). Secondary endpoints (compliance, health
care utilization, lung function parameters, use of rescue
medication, health-related quality of life [St. George’s
Respiratory Questionnaire, SGRQ-C], COPD-related direct
costs and safety) were analyzed by calculating frequencies
and/or by providing descriptive summary statistics. Com-
pliance was calculated on the basis of residual doses in the
inhalation device returned by the patient. For com-
parability reasons SGRQ-C scores were transformed to SGRQ
scores according to the instructions in the manual of the
questionnaire. Thus, SGRQ scores are reported exclusively.
Results
Patient disposition
In total, 213 COPD patients (from 23 centers) who were well
balanced between the two treatment groups (SFC singleinhaler: 108 patients, Sal/FP separate inhalers: 105 pa-
tients) were evaluated in this study (safety population).
The majority of patients (80.6% under SFC and 75.5% under
Sal/FP) completed the study; adverse events were the most
frequent reason for study discontinuation (9.3% in the SFC
group and 9.4% in the Sal/FP group). None of the patients in
either group had to be withdrawn due to non-compliance.
Patient disposition is displayed in Fig. 1. If not mentioned
otherwise, results are presented for the ITT population
which comprised 107 patients in the SFC group and 105
patients in the Sal/FP group.
Demography and other baseline characteristics
Demographic data and baseline characteristics are sum-
marized in Table 1. More than twice as many males than
females were enrolled into this study. Baseline results of
blood gas analyses and lung function tests reflected the
patients’ respiratory impairment. The prior COPD medi-
cation most commonly used were anticholinergics (72.2% in
the SFC group versus 82.9% in the Sal/FP group). The pro-
portion of patients who were pre-treated with long-acting
beta2-agonists (LABAs, 20.7% in total group) was higher in
the SFC group (25.0%) than in the Sal/FP group (16.2%). A
minimal difference between the treatment groups was also
observed with regard to prior use of inhaled corticosteroids
(13.9% for SFC versus 11.4% for Sal/FP, total: 12.7%) and
prior use of the combination of LABA plus inhaled cortico-
steroid (12.0% for SFC versus 9.4% for Sal/FP, total 10.7%).
On average the patients had suffered 2.3  0.6 moderate or
severe exacerbations in the preceding year.
A total of 156 patients were - according to their baseline
FEV1 value - classified as having severe (GOLD Stage III)
COPD and 56 patients as having very severe (GOLD Stage IV)
COPD. The proportion of patients with very severe COPD
was slightly higher in the SFC group (28.0%) than in the Sal/
FP group (24.8%).
COPD exacerbations
As displayed in Table 2, the annual rate of moderate or
severe exacerbations was almost identical in both treat-
ment groups (0.86  0.13 in the SFC group versus
0.86  0.14 in the Sal/FP group) with an exacerbation rate
ratio SFC/Sal/FP of 1.00 (p Z 0.73; negative binomial
model).
60.7% of patients under SFC and 58.1% of patients under
Sal/FP did not experience any exacerbation during the
study period and approximately one quarter of the patients
in each treatment group developed only 1 exacerbation.
The majority of exacerbations were moderate (51 of 80
[63.8%] exacerbations under SFC and 51 of 74 [68.9%] ex-
acerbations under Sal/FP); severe exacerbations were
slightly more frequent under SFC (26 exacerbations; 32.5%)
as compared to Sal/FP (18 exacerbations; 24.3%). A
patient-based analysis of exacerbation severity showed
that the proportions of patients with severe exacerbations
(15.0% under SFC versus 13.3% under Sal/FP) were compa-
rable in both treatment groups.
The first exacerbation occurred after a mean (standard
error) of 38.9  1.8 weeks (25th percentile: 25.6 weeks) in
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weeks) in the Sal/FP group (KaplaneMeier estimates).
Compliance
Treatment compliance (number of used doses divided by
expected use, given in percent) was very high and compa-
rable in both treatment groups (97.1  11.6% in the SFC
group vs. 98.4  19.6% in the Sal/FP group).
Health care utilization
Overall, less than half of the patients reported medical
visits due to COPD in addition to the study visits. Most
frequent were visits to the physician’s office (40.2% of pa-
tients) whereas home visits (8.2%) and visits to the emer-
gency medical service (4.6%) were relatively rare. Home214 pts. ran
108 pts. randomized to SFC (100.0%)
108 pts. received SFC
21 (19.4%) pts. discontinued
10 (9.3%) due to adverse events
5 (4.6%) patient’s wish
3 (2.8%) lost to follow-up
3 (2.8%) other reasons
87 (80.6%) pts. completed the study
1 pt. had mixed asthma
107 pts. (ITT population)
Figure 1 Patienvisits by an emergency physician were more frequent in the
SFC group (13 patients; 13.3%) than in the Sal/FP group (2
patients; 2.1%).
Hospitalizations for any reason were reported for 23.4%
of patients in the SFC group and for 17.1% of patients in the
Sal/FP group. On average, patients under SFC spent
21.9  23.1 days in hospital (2.2  8.4 days in the intensive
care unit) and patients under Sal/FP 18.1  18.0 days in
hospital (1.0  2.6 days in the intensive care unit).
COPD-related direct costs
As could be expected the total COPD-related direct costs
per patient during the study as well as the costs of the in-
dividual factors included (i.e. hospital stays, visits to
a doctor and COPD medication; study medication excluded)
varied greatly. The mean values for the total costs were
distorted by a small number of very high values originating26 (24.5%) pts. discontinued
10 (9.4%) due to adverse events
8 (7.5%) patient’s wish
2 (1.9%) lost to follow-up
6 (5.7%) other reasons
domized
106 pts. randomized to Sal/FP (100.0%)
105 pts. received Sal/FP
80 (75.5%) pts. completed the study
1 pt. did not receive Sal/FP
105 pts. (ITT population)
t disposition.
Table 1 Demography and other baseline characteristics (ITT population).
SFC (N Z 107) Sal/FP (N Z 105)
Sex [n (%)] Male 74 (69.2) 76 (72.4)
Age [years] 65.5  8.3 (67.0) 64.2  8.9 (64.0)
Smoking status [n (%)] Ex-smoker 74 (69.2) 78 (74.3)
Smoker 33 (30.8) 27 (25.7)
Pack years 39.2  16.6 (39.0) 40.4  24.1 (34.0)
Duration of COPD [years] 12.4  7.3 (10.5) 13.3  8.3 (10.6)
No. of exacerbations (preceding 12 months) 2.2  0.5 (2.0) 2.3  0.6 (2.0)
No. of hospitalizations due to COPD
(preceding 12 months) [n (%)]
0 84 (78.5) 87 (82.9)
1 19 (17.8) 15 (14.3)
2e4 4 (3.7) 3 (2.9)
Prior (within 4 weeks prior to baseline)
treatment with [n (%)]:
Anticholinergics 78 (72.2) 87 (82.9)
LABAs 27 (25.0) 17 (16.2)
Inhal. corticosteroids 15 (13.9) 12 (11.4)
LABA þ inh.
corticosteroids
13 (12.0) 10 (9.4)
pO2 [mmHg] 63.3  9.0 (63.0) 64.1  9.4 (64.0)
SO2 [%] 91.9  3.7 (92.8) 91.8  4.0 (93.0)
Pre bronchodilator FEV1 [L] 1.0  0.3 (1.0) 1.1  0.3 (1.0)
Post bronchodilator FEV1 [L] 1.0  0.3 (1.0) 1.1  0.3 (1.1)
Reversibility [%)] 3.1  10.6 (3.1) 4.6  14.8 (2.5)
FEV1/IVC ratio [%] 48.9  11.1 (47.4) 49.1  10.8 (47.8)
FEV1 [% predicted] 36.8  8.9 (36.4) 38.2  9.3 (38.8)
Values are presented as mean  standard deviation (median) unless stated otherwise.
FEV1 Z Forced expiratory volume in 1 s.
IVC Z Inspiratory vital capacity.
LABA Z Long-acting beta2-agonists.
pO2 Z Partial pressure of oxygen; SO2 Z Oxygen saturation (in arterialized capillary blood).
SD Z Standard deviation.
SFC Z Salmeterol xinafoate/fluticasone propionate (50/500 mg) single inhaler.
Sal/FP Z Salmeterol xinafoate 50mg þ fluticasone propionate 500 mg separate inhalers.
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patient amounted to V 831 in the SFC group and V 872 in
the Sal/FP group (range for total costs in total group: V
0e18.763).Lung function
As summarized in Table 3 and depicted in Fig. 2, lung
function (assessed by mean post-bronchodilator FEV1,
inspiratory vital capacity [IVC] and Tiffeneau Index [FEV1/
VC]) showed a minimal initial improvement after 8 weeks of
treatment and remained stable throughout the further
study period. There were no clear differences observed
between the treatment groups.f Range 0e100 with high values representing poorer quality of
life. Minimum clinically important difference for individual as well
as group-changes is 4 units. SGRQ-C scores have been transformed
to SGRQ scores and are reported as such.Use of rescue medication
The frequency of rescue medication use was comparable in
both treatment groups. At the final visit rescue medication
use was recorded for 5.0  2.5 (median: 7.0; change from
Visit 2: 0.3  2.4) days of the preceding week in the SFC
group and for 4.7  2.7 (median: 6.0; change from Visit 2:
0.6  2.5) days of the preceding week in the Sal/FP group.Health-related quality of life (St. George’s
Respiratory Questionnaire, SGRQ-C)
Mean baseline SGRQf total scores (57.8  17.1 in the SFC
group and 55.9  15.4 in the Sal/FP group) indicated that
health-related quality of life was similarly impaired in both
treatment groups. Only minimal improvements were
observed during the course of the study and no clear dif-
ferences were seen between the treatment groups. At
Week 52 the total score had decreased by 1.8  14.4 to
56.0  18.2 in the SFC group and by 2.6  14.7 to
53.3  17.7 in the Sal/FP group. The greatest changes were
observed in the symptom score which decreased from
68.8  19.7 to 65.4  19.8 (difference of 3.4  17.7) in
the SFC group and from 69.0  18.4 to 63.8  19.9 (dif-
ference of 5.2  17.3) in the Sal/FP group.
Safety
Besides COPD exacerbations, pneumonia (5.6%) and naso-
pharyngitis (5.2%) were the most common adverse events
Table 2 Comparative analysis of exacerbation rate (ITT population).
SFC Sal/FP SFC versus Sal/FP p-value
Negative binomial modela Ratio
LS-means  SE 0.86  0.13 0.86  0.14 1.00  0.22 0.73
Raw rates (Znot adjusted) e e
Mean  SD 0.81  1.45 0.98  2.12
Number of exacerbations N Z 107
n (%)
N Z 105
n (%)
Difference % 95%-CI
0 65 (60.7) 61 (58.1) 2.7 [10.6; 15.9]
1 26 (24.3) 25 (23.8) 0.5 [11.0; 12.0]
2 6 (5.6) 12 (11.4) 5.8 [13.3; 1.7]
>2 10 (9.3) 7 (6.7) 2.7 [4.6; 10.0]
At least 1 42 (39.3) 44 (41.9) 2.7 [15.9; 10.6]
Severity of exacerbations (event-based) N (events) Z 80 n (%) N (events) Z 74 n (%)
Mild 3 (3.8) 5 (6.8)
Moderate 51 (63.8) 51 (68.9)
Severe 26 (32.5) 18 (24.3)
SD Z Standard deviation.
SE Z Standard error.
SFC Z Salmeterol xinafoate/fluticasone propionate (50/500 mg) single inhaler.
Sal/FP Z Salmeterol xinafoate 50mg þ fluticasone propionate 500 mg separate inhalers.
a Adjusted for COPD severity and interaction between treatment and COPD severity, using a strata imbalance of 73% (severe COPD)
versus 27% (very severe COPD).
Table 3 Lung function (ITT population).
SFC (N Z 107) Sal/FP (N Z 105)
FEV1 (% predicted)
Baseline 36.8  8.9 38.2  9.3
Week 8 40.8  12.1 41.4  12.9
Week 52 39.0  13.2 41.2  15.3
Difference
baseline e week 52
2.2  10.4 3.1  12.1
IVC (liters)
Baseline 2.17  0.74 2.29  0.71
Week 8 2.27  0.76 2.37  0.72
Week 52 2.14  0.72 2.27  0.68
Difference
baseline e week 52
0.02  0.53 0.02  0.50
Tiffeneau index
(FEV1/IVC) (%)
Baseline 48.0  11.1 49.1  10.8
Week 8 51.2  12.6 51.2  13.4
Week 52 50.8  11.0 52.8  16.4
Difference
baseline e week 52
1.9  8.8 3.8  13.4
Please note: Missing values were replaced by “last observation
carried forward” (LOCF).
Values are presented as mean  standard deviation.
FEV1 Z Forced expiratory volume in one second.
IVC Z Inspiratory vital capacity.
SFCZ Salmeterol xinafoate/fluticasone propionate (50/500 mg)
single inhaler.
Sal/FP Z Salmeterol xinafoate 50mg þ fluticasone propionate
500 mg separate inhalers.
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frequent in the Sal/FP group (65.7% versus 55.6% in the SFC
group), adverse drug reactions (i.e. AEs with a possible
causal relationship) were slightly more frequent in the SFC
group (10.2% versus 5.7% in the Sal/FP group). Except for
dysphonia, dyspnea and oral candidiasis all of the drug-
related events occurred in individual patients only. AEs
leading to premature study discontinuation (total: 8.9%)
and AEs with outcome ‘not recovered’ (total: 7.5%) were
reported at similar rates in both treatment groups. Serious
adverse events occurred slightly more frequently under SFC
(21.3%) than under Sal/FP (15.2%), however, a drug-
relationship was only assumed in 1 patient in the Sal/FP
group (SAEs: arrhythmia, [exacerbation of] chronic
obstructive pulmonary disease, cyanosis and dyspnea). OneFigure 2 Course of mean forced expiratory volume in one
second (FEV1).
548 C. Hagedorn et al.patient in the SFC group and 2 patients in the Sal/FP group
died; none of the deaths were considered to be drug-
related. Mean blood pressure and heart rate neither
showed relevant changes during the study nor clear dif-
ferences between the treatment groups.Discussion
A total of 213 patients (156 GOLD Stage III and 56 GOLD Stage
IV) were evaluated in this study. Hence, the study population
included a proportion of approximately 25% of patients with
very severe COPD. Although the prevalence of COPD in
women has increased in recent years, more than twice as
many males than females were enrolled into this study. Even
with a mean duration of COPD of more than 10 years in the
total population more than 25% of patients were still active
smokers. Considering the fact that smoking is connectedwith
a greater COPD mortality rate and quitting smoking can
reduce its progression, there seems to be room for improve-
ment in patient education and the need for the imple-
mentation of comprehensive smoking cessation programs.
The annual rate of moderate or severe COPD exacerba-
tions was almost identical in both treatment groups. The
underlying assumption that fixed combination therapy
might lead to a lower rate of exacerbations due to better
compliance versus the separate inhalers was not supported
in this study as compliance rates were similar in both
groups. It has previously been shown that patient com-
pliance in COPD under real-life conditions is often poor13
and that repeated instruction for inhalation techniques
may result in improved compliance.14 Although we specifi-
cally chose a study design which was relatively close to
real-life conditions the patient’s awareness of participating
in a study and the closer monitoring nevertheless seem to
have positively influenced medication adherence. Since
pre-post changes in compliance were not evaluated a se-
lection of particularly compliant patients by the in-
vestigators can furthermore not be excluded.
The annual exacerbation rates in our study were quite
low, in particular when considering the fact that 25% of
patients suffered from very severe COPD. In the TORCH
study, patients with severe COPD who were treated with
SFC showed an annual exacerbation rate of 0.91 and pa-
tients with very severe COPD a rate of 1.54.15 Annual
exacerbation rates under SFC which were comparable to
the rates in our study were observed by Kardos et al.9 (0.92)
and in a Chinese study (0.81).16 Exacerbation rates in ran-
domized clinical studies which often exclude patients with
severe co-morbidities tend to be lower than those reported
in observational studies which reflect the “true” COPD
population more closely. Hurst et al.11 who identified
a positive association between an impaired health status
and exacerbation frequency observed annual exacerbation
rates of 1.34 in patients with severe and 2.00 in patients
with very severe COPD. The low exacerbation rates in our
study, however, made it difficult to identify a difference
between the use of a single or two separate inhalers.
Taking into account the reported baseline exacerbation
rate (on average 2.3  0.6 exacerbations within the pre-
ceding year) and the fact that patients were required to
have suffered 2 or more moderate or severe exacerbationsin the preceding year to be eligible for inclusion, the rate of
exacerbations observed in our study seemed to have been
reduced, particularly when considering that 60.7% of pa-
tients in the SFC group and 58.1% of patients in the Sal/FP
group did not suffer any exacerbation during the study. This
result, however, has to be interpreted with care since
baseline data on exacerbations were based on retro-
spective patient reports in which the exacerbation fre-
quency might have been overestimated or over-reported
based on the known inclusion criterion. Nevertheless,
a reduction in the exacerbation rate in these COPD GOLD
Stage III or IV patients could have been induced by the
change in therapy since only 20.7% of patients had been
pre-treated with LABAs and 10.7% with LABA and ICS in
combination. The good compliance during the study
together with a close monitoring and awareness of study
participation might have played a significant additional role
explaining this phenomenon.
The majority of exacerbations in our study were of
moderate severity. Analysis of exacerbation severity on an
event-basis pointed to a trend towards a slightly higher rate
of severe exacerbations and a slightly lower rate of mild or
moderate exacerbations under SFC as compared to Sal/FP.
Correspondingly, the rate of home visits by an emergency
physician was higher in the SFC group. A contributing factor
to this observation could be the somewhat higher propor-
tion of Gold Stage IV patients in the SFC group; also, the
rate of COPD-related hospitalizations in the 12 months
preceding the study was slightly higher in this group. On the
other hand, a patient-based analysis of exacerbation
severity showed similar proportions of patients with severe
exacerbations in both treatment groups.
Due to the fact that less than half of the patients in our
study suffered an exacerbation during the observation
period the median time to first exacerbation could not be
estimated in the KaplaneMeier analysis. Taking the mean
and the 25th percentile into account, the occurrence of the
first exacerbation seemed to be slightly delayed under SFC.
With regard to the analysis of health care utilization it
needs to be taken into consideration that the data were
based on patients’ self reports collected mainly via tele-
phone interviews. Although the time period covered by the
8- or 4-weekly intervals was relatively short, self-reports
carry the possibility of inaccuracy due to under-or over-
reporting.
Lung function showed minimal initial improvement after
8 weeks of treatment and remained stable throughout the
further study period.
With regard to quality of life no clinically relevant im-
provements were observed in either treatment group dur-
ing the course of the study. The greatest change pointing
towards an improvement was seen in the symptom score.
Treatment was safe and well tolerated in both treat-
ment groups and the safety profile was overall in line with
previous reports.16,17
In conclusion, this exploratory study did not show any
substantial difference in the treatment of COPD when sal-
meterol xinafoate/fluticasone propionate was adminis-
tered in a fixed combination via a single inhaler as
compared to the application via separate inhalers. Lung
function and quality of life were maintained over 1 year
and observed exacerbation rates were lower than those
Salmeterol/fluticasone in COPD GOLD Stage III/IV 549reported at baseline. Compliance was very high and com-
parable in both treatment groups. Treatment was safe and
no new safety issues were identified.
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